Edesa Biotechの価格/簿価
Edesa Biotechの価格/簿価は何ですか。
Edesa Biotech, Inc.の価格/簿価は2.47です。
価格/簿価の定義は何ですか。
株価純資産倍率は、会社の株価と1株当たりの簿価との比率を表します。
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
NASDAQのセクタHealth Careにおける価格/簿価の企業と比べるEdesa Biotech
Edesa Biotechは何をしますか。
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotechと類似の価格/簿価
- Kezar Life Sciences Incの価格/簿価は2.47です。
- Flight Centre Travelの価格/簿価は2.47です。
- The Anup Engineeringの価格/簿価は2.47です。
- Bellerophon Therapeutics Incの価格/簿価は2.47です。
- Ningbo Solartron Technology Coの価格/簿価は2.47です。
- Hansard Global Plcの価格/簿価は2.47です。
- Edesa Biotechの価格/簿価は2.47です。
- Village Roadshowの価格/簿価は2.47です。
- Biogenの価格/簿価は2.48です。
- Heineken NVの価格/簿価は2.48です。
- Compassの価格/簿価は2.48です。
- Macrogenics Incの価格/簿価は2.48です。
- Arvindの価格/簿価は2.48です。